Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

The problem with COPD is you have obstruction ... improve patients' breathing and decreases the exacerbations. And there are a host of medications we can use now that barely existed or didn ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

[8] The analysis concluded that these drugs, taken long term, could be most useful in patients who have repeated, prolonged or severe exacerbations of COPD. Hence, in some European and extra ...

In its phase 3 ENHANCE programme, the drug was shown to reduce exacerbation rate and risk over 24 weeks in COPD patients, regardless of blood eosinophil levels, compared to placebo, and also ...

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...